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ABSTRACT
Background. Managing patients with nephrotic syndrome
(NS) remains difficult for the practicing nephrologist. This
often young patient population is faced with a debilitating, re-
lapsing and remitting disease with non-specific treatment op-
tions that are often poorly tolerated. Clinicians managing
these complex patients must attempt to apply disease-specific
evidence while considering the individual patient’s clinical
and personal situation.
Methods.We conducted qualitative interviews to ascertain the
provider perspectives of NS, treatment options and factors that
influence recommendations for disease management, and ad-
ministered a survey to assess both facilitators and barriers to
the implementation of the Kidney Disease: Improving Global
Outcomes (KDIGO) guidelines.
Results.When making treatment recommendations, providers
considered characteristics of various treatments such as efficacy,
side effects and evaluation of risk versus benefit, taking into ac-
count how the specific treatment fit with the individual patient.
Time constraints and the complexity of explaining the intrica-
cies of NS were noted as significant barriers to care. Although
the availability of guidelines was deemed a facilitator to care, the
value of the KDIGO guidelines was limited by the perception of
poor quality of evidence.
Conclusions. The complexity of NS and the scarcity of robust
evidence to support treatment recommendations are common
challenges reported by nephrologists. Future development and
use of shared learning platforms may support the integration of
best available evidence, patient/family preferences and ex-
change of information at a pace that is unconstrained by the
outpatient clinic schedule.
Keywords: KDIGO guidelines, learning needs, nephrotic syn-
drome, qualitative approaches, treatment decision-making
INTRODUCTION
Patient-centered approaches are widely recognized as a priority
for delivering high-quality health care [1, 2]. While there is
no agreed-upon definition, patient-centered practices include:
consideration of an individual’s understanding and concerns
regarding their condition, recognition of personal circum-
stances, establishment of a common understanding of the prob-
lem to be addressed and agreement on the treatment approach,
using best evidence to support management decisions [2, 3].
Thus, patient-centered approaches require a shared approach
to learning and decision-making between the patient/family
and the healthcare provider.
© The Author 2017. Published by Oxford University Press
on behalf of ERA-EDTA. All rights reserved.
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Delivery of patient-centered care (PCC) can be particularly
challenging in the management of nephrotic syndrome (NS)
because the patient and health care team face a series of deci-
sions that unfold over time due to the significant associated
chronic illness state, typically characterized by edema, fatigue
and hypercoagulability, as well as the relapsing, remitting and
progressive nature of NS. Further challenges also derive from
the often poor response to therapies that are accompanied by
serious potential side effects and toxicities.
Clinical practice guidelines attempt to comprehensively
assess and synthesize the medical literature into a practical con-
text for the practicing physician. The Kidney Disease: Improv-
ing Global Outcomes (KDIGO) Clinical Practice Guideline for
Glomerulonephritis is based on a systematic review, appraisal
and synthesis of the literature available through November
2011 [4]. Within these guidelines, evidence is rated and graded
recommendations are provided based on evidence where avail-
able and expert opinion when evidence is lacking. From the
provider perspective, merging knowledge of disease-specific
evidence along with consideration of the individual patient’s
clinical and personal situation provides a particular challenge
in delivering PCC. However, little attention has been given to
examining provider perspectives about treatment decision-
making in NS or the factors providers take into account inmak-
ing treatment recommendations.
We therefore examined patient, family and provider per-
spectives on NS (Phase I) to develop a shared learning decision
support tool (Phase II). In this paper, we report only on pro-
vider perspectives from Phase 1, with a specific focus on the
decision-making process including factors providers take into
account when making treatment recommendations as well as
their impressions of the clinical practice guidelines for theman-
agement of primary glomerular diseases causing NS.
MATERIALS AND METHODS
A sequential mixedmethods approach [5] was used to elicit and
analyze provider perspectives on health-related decision-
making in NS.
Subjects
Providers with the primary responsibility for the medical
management of children or adults with incident NS were in-
vited to participate. NS was defined as urine protein loss caus-
ing hypoalbuminemia and edema caused by steroid-sensitive
(SS) or -resistant (SR) NS in children, minimal change disease
(MCD), focal segmental glomerulosclerosis (FSGS) or mem-
branous nephropathy (MN) in children or adults. Participants
were recruited by the three participating centers: the University
of Michigan, the University of North Carolina at Chapel Hill
and the University of Toronto, as well as through the Nephrotic
Syndrome Study Network (NEPTUNE; Neptune-study.org).
Internal medicine and pediatric providers were included and
input from academic as well as community practices was
sought. The study was conducted with the approval of the
Human Subjects Research Ethics Board at all participating cen-
ters, and all participants provided informed consent.
Data collection
Between December 2012 and April 2014, qualitative ap-
proaches (focus groups and individual interviews) were used
to elicit provider perspectives about treatment decision-making
in NS.At the completion of the qualitative interviews, providers
were asked to complete a Practice Guideline Questionnaire
(PGQ), developed by the research team on the use of practice
guidelines in general, and specifically, the KDIGO guidelines
for glomerulonephritis.
Qualitative data
A semi-structured interview guide was developed, reflecting
patient-centered communication and shared decision-making
[6]. Interview questions were informed by the Population
Needs Assessment based on the Ottawa Decision Support
Framework [7]. Interview guides were reviewed for comprehen-
siveness and clarity by the project steering committee and were
pilot tested for validation of the content. Providers were invited
to discuss their perspectives about key decisions patients and par-
ents facedwhen diagnosedwith NS, themain options for therapy
and considerations when recommending a treatment option, as
well as barriers to and supports of the decision-making process.
Focus group sessions were ∼1 h and were guided by two ex-
perienced interviewers/facilitators from each respective site. All
had experience in qualitative interviewing and were trained
with respect to the project specifics to ensure consistency of ap-
proach to data collection. One interviewer was responsible for
facilitating the discussion using the interview guide and the se-
cond assisted with timekeeping and kept field notes about the
group sessions (e.g. observations of group interactions). Indi-
vidual interviews were conducted by one interviewer using
the same interview guide. All focus group and interview ses-
sions were audiotaped.
Practice Guideline Questionnaire
In the first part of the PGQ, respondents were provided
with a list of possible facilitators and barriers to the use of guide-
lines adapted from the existing literature [8], and were asked to
identify which applied to their practice. In the second part of
the PGQ, participants were asked to consider five specific
KDIGO guidelines for the management of NS (SSNS in Chil-
dren; SRNS in Children; MCD in Adults; Idiopathic FSGS in
Adults; and Idiopathic MN). Pediatric nephrologists were
asked to complete the child-specific guideline assessment and
internal medicine nephrologists were asked to complete the
adult-specific guideline assessment. Respondents were pro-
vided with a summary of each guideline developed by the re-
search team and asked to evaluate whether guidelines were
consistent with and acceptable for current practice. If guidelines
were deemed unacceptable, providers were asked to select from
a list of possible reasons. In the final part of the questionnaire,
participants were invited to provide any additional feedback
about implementing practice guidelines in general or KDIGO
guidelines in particular. The PGQwas reviewed for comprehen-
siveness and clarity by the project steering committee and three
nephrologists on the team reviewed the guideline summaries
for validation of content.
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Sample size and data analysis
A total of 38 providers participated in the qualitative compo-
nent of our study. This sample size is consistent with qualitative
research standards. Further, in keeping with purposive sampling
approaches used in qualitative research, our goal was to include a
sample of providers representing a variety of diverse experiences
and perspectives. Thus, we included participants from multiple
sites and various practice settings, with a range of practice experi-
ences, which helps to enhance the transferability of our findings.
With respect to the quantitative portion, the sample size pro-
vided ∼80% power to detect a 20% difference between groups.
Audiotapes of focus group and individual interviews were tran-
scribed verbatim. Transcripts were coded using a coding frame-
work developed inductively by the research team and analyzed
using a qualitative content analysis approach [9]. Coding and ana-
lysis was undertaken with the computer program NVIVO 10. Re-
sponses to the PGQ items were tabulated using frequency counts,
and descriptive statistics were used to characterize the sample.
RESULTS
Between December 2012 and April 2013, four focus groups and
two individual interviews were conducted with a total of 38 par-
ticipants. Of these, 35 provided detailed demographic data, and
33 completed the PGQ.
Characteristics of respondents and prescribing practices
related to the treatment of NS
Based on location of practice, there were 11 participating
Canadian physicians, 24 American physicians and 3 who failed
to provide demographic data. The participating American phy-
sicians represented eight states and all the Canadian physicians
practiced in Ontario. The median age of participating physi-
cians was 53 years (range 31–71 years), and 61% were male.
The majority had in excess of 10 years of experience practicing
in the field (median 16.5 years; range 0.5–35 years). The ma-
jority were nephrologists that cared exclusively for adult pa-
tients (61%) and practiced in academic centers (55%), while
45% practiced in either community hospitals or private
practice. A minority of the physicians affiliated with academic
centers worked in large dedicated GN clinics. All providers
were aware of the KDIGO guidelines, and 90% stated they
had read them. All providers had prescribed immunosup-
pressive agents to manage patients with NS within the preced-
ing 2 years.
Qualitative findings
Provider perspectives of the decision-making process in NS
included three broad categories: (i) factors providers take into
consideration when making treatment recommendations; (ii)
providers’ perception of patients’ and parents’ learning needs;
and (iii) providers’ perception of factors affecting the decision-
making process.
Factors providers take into consideration when making
treatment recommendations
When making treatment recommendations, providers con-
sidered characteristics of various treatments, such as efficacy,
side effects and evaluation of risk/benefit, and took into account
how treatment options fit with an individual patient or child
(Table 1). The patient characteristicsmost commonly considered
Table 1. Provider considerations for making treatment recommendations
Characteristics of the patient/parent/child
Demographic characteristics (age, sex, family history)
‘If we’re thinking about Cytoxan we’re thinking about the age of the child and the toxicity.’
‘The patient age group because if it’s a teenager, it’s even more of an issue in terms of physical appearance.’
‘If they’re a female, and they’re young, and they’re in their childbearing age, we have to take that into account, too. Even for general therapy because ACE inhibitors—
could have an effect on the unborn child. Some medications can affect their fertility too.
‘In pediatrics, especially we’ll think about if there’s a family history of nephrotic syndrome. If we believe this is a genetic form of nephrotic syndrome, we may choose not
to use immunosuppressant therapy.’
Clinical characteristics (diagnosis/prognosis/disease severity, comorbidities)
‘…It is easier when I have diagnostic certainty. So when a patient who is four years old presents with a classic presentation minimal change nephrotic syndrome, it’s
easy for me to sit down confidentially and tell the family this is what we should do. If it’s a teenage boy with severe FSGS, interstitial inflammation, and chronic
kidney disease, it’s also an easier conversation because there aren’t options. Once you get to those grey zones you sort of have to have complicated conversations where
we’re not sure which is the right immunosuppression.’
‘There also may be different patient specific characteristics that come into play more in the considerations with adults compared to children. Comorbid conditions
need to be considered when deciding what agent to choose.’
‘What is the down side to using steroids? Even though they’re indicated, do the down sides outweigh the benefits of therapy?’
Psychosocial and socio-economic considerations (adherence of patient/parent/child financial resources)
‘We think about how compliant or adherent the family is, especially for meds that need monitoring like tacrolimus or cyclosporine.’
‘Another issue that our patients encounter is the inability to pay the bills. So a major factor in deciding which drug to use in our patients is based on affordability of
the drug.’
Patient preference
‘Their own subjective risk assessment… Some people really don’t want to be on dialysis and they’re willing to risk death not to go on it… Everybody’s afraid of
something different. Other people don’t want the cancer risks from the Cytoxan… you have to give them the different choices so they can pick and choose the path
they want to go down.’
‘I also worry about other side effects in general for patient preference.… some of these medications have pretty severe GI side effects, and I definitely talk to my
patients about…what side effects really they’re most worried about… I think there’s a whole range of side effects that are different for different patients.’
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included the severity of the disease and prognosis, as well as
demographic characteristics of the patient (age, sex). Psycho-
social considerations, such as socio-economic status and
adherence/compliance, were also considered important. While
providers highlighted issues of concern for particular groups of
patients (e.g. fertility for young women), they also discussed the
importance of understanding patient/parent opinions about spe-
cific treatment options when making recommendations.
Provider’s perceptions of learning needs of patients
and parents
When asked what information patients and parents should
know, the most prevalent learning needs providers identified
were related to understandingNS and its implications (Table 2).
In addition to helping patients and parents understand kidney
disease in general, providers highlighted the importance of spe-
cifically learning about NS. This included understanding the
diagnosis and prognosis, understanding the complexities of
the disease and the treatment of NS in general, as well as the
specific approach recommended for their individual situation.
In some instances, this involved helping patients/parents
understand the need to gather more diagnostic information be-
fore making a treatment recommendation. Since medications
were an essential component of the approach to treatment for
most patients, providers felt it was important for patients/par-
ents to have information about side effects, duration of treat-
ment and risk/benefits of taking these medications over the
short and long term. However, presenting this information to
patients was seen as particularly challenging due to the lack
of information targeting their unique concerns. Providers
noted the importance of explaining the chronic nature of the
condition. Further, the remitting, relapsing nature of NS was
identified by a number of providers as being a particularly dif-
ficult aspect for some patients and parents to grasp andmanage.
Many providers felt that the complex nature of NS and its
management was often challenging for patients and parents
Table 2. Providers perceptions of patients’ and parents’ informational needs
Understanding NS and the treatment journey
Understanding the diagnosis
‘They have to learn about the disease, and that it’s relapsing and remitting; and that’s complex to understand.’
‘… Some patients need to have some distinction between… a kidney disease per se and voiding. They have that confusion becausewhen they come to see you they say
‘I don’t know why I’m here for, I’m peeing well.’
Understanding the prognosis
‘Two other things I think they need to hear, one is the course of the disease in question. If we’re talking about FSGS, how likely is it to progress and what are the
consequences… if steroids don’t work? In terms of dialysis and transplant, what might the timing be? What do those look like? Again, all in this 20-minute time
span… Then what are the expected response rates and relapse rates for their particular type of FSGS or minimal change disease?’
‘… they want us to give them a prognosis, but unfortunately, we can only prognosticate depending on how often we see them, and how often the disease relapses. At
their first presentation, they want me to tell them if it’s ever going to come back, and I can’t. I can only just say in a 100 children, it will come back in 70%whowill go
on and have one relapse. But out of those maybe 5 or 10% will progress to end-stage renal disease. They want to know where they fit already, and I can’t give them a
prognostic view at that very first visit. I think that’s the hardest part.’
Knowing what diagnostic tests will be done
‘I find that lots of times, patients come in with urine analysis 3 plus. The first step forme is explaining to the patient they need to confirm this, the second step involves
a kidney biopsy because we need to have a firm diagnosis, a definitive diagnosis.’
‘They also have to learn how to dip their urine every morning, sowe teach them to dip the urine. They have to be trained in how to do that, and to understand what a
relapse means, what protein in the urine means; and then agree to be able to do that each day.’
Understanding the approach to treatment
‘They want to know how long they need to be treated with a drug that may or may not be toxic.’
‘I think that they clearly should have a sense of themajor side effects of each of the options. Now of course all these drugs have innumerable side effects so you can only
go so far in terms of informed consent and howmuch weight do you give to each possibility is going to be amatter of your style… but they need the major side effects
and the beneficial effects in terms of what type of time frames things are likely to improve if they’re going to improve…’
‘Medication-wise, there are a lot of issues about starting multiple medications. From the patient’s perspective, it’s immediate symptom control, but then from the
physician’s perspective, it’s more symptoms plus decisions about conservative therapy versus using immunotherapy.’
Understanding the complexities of the disease
‘I think it’s difficult for the parents to understand that this is a relapsing and remitting disease, and that in fact, studies have shown; the more that we treat it at the
beginning the better, so this is really our best chance to treat the underlying disease; and let’s treat it the best way. That they find hard because once it goes away, they
want to stop the medication, so you have to convince them that in fact studies have shown 12 to 16 weeks have been really good in diminishing relapses down the
road…’
Tailored information
‘So they often feel, I think—sometimes, I feel as well—that there wasn’t really a good communication with what’s actually going to happen to them becausewe’re not
exactly sure at that point;… they’ve just comewith protein in the urine. That covers a very large and very wide spectrum of the disease process. I think the idea about
trying to account for what it is that we tell the patient and what they receive is sometimes not a very good match.’
I’d say first thing it has to be tailored to the level of understanding of the family… here’s your relapse risk…, but I can tell you an awful lot of my patients, whether
they’re English or, as in the majority, Spanish speaking, would not understand that. They would not understand what a percentage is, so it has to be fairly nuanced
in terms of covering things, but not being confusing. That’s the problem I have with online material. You can go to something that’s absolutely correct and they come
in and think my baby’s going to die tomorrow and you look at it and you say, ‘That’s right. It just doesn’t apply to your baby.’ It can be true information but not
relevant here, and they don’t know that.
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Table 3. Providers’ perceptions of barriers and facilitators to the decision-making process
Barriers
Time constraints
‘You know this is again going back to the time issue. I mean there’s a lot to compress into a single visit and of course there’s immediate information overload so I
think what do they say you get two or three things out of a visit you know that a patient will remember, and we have to tell them fifteen different things.’
‘… the time issues is twofold. One is not having enough time talking with the patient because you don’t have enough time in your clinic visit, but the other is that
sometimes we have time pressure to make therapeutic decisions that people are not ready to make because they’re tough decisions.’
Complexity of NS and its treatments
‘I mean virtually all these diseases have… a literature that’s a text book size and if you have to give them the balance of… the risk, but in proportionate to the need
for therapy… There’s a lot of editing involved because if you spend all your time talking about the risks of therapy, the patient is not going to choose therapy and in
the long term what’s best for the patient may well be therapy.’
Patient/parent emotional response to the diagnosis
‘Renal disease isn’t… as common as heart disease or cancer and patients know that if you go see a Nephrologist, you’re in trouble. So, the emotions are already there
up front, people are anxious about it.’
‘I don’t think there’s a pattern, they’re just mad. They don’t want this diagnosis. They don’t believe a word you’re saying. It’s sort of the anger denial. They’re in
denial, they’re not ready to have a discussion and they’re very suspicious. Basically you spend the whole time answering defensive questions and stuff that’s not
relevant. That’s not getting towards an actual treatment plan.’
Misperceptions about kidney disease and NS
‘…when it comes to kidney disease in general, there’s less appreciation for different types of kidney disease so often the patient will come with sort of the wives tales
of… does cranberry juice help this and stuff like this. They’re applying the antidotes in the common wisdom that may apply to urinary tract infections or kidney
stones to this disease. Unlike for instance hypertension or heart disease, where there’s been a lot of public education, for kidney disease there has not been…’
‘Patients need to know about the prognosis… I’m not sure whether all patients really understand that this disease could lead to dialysis and they don’t even know
what dialysis means. So I think if they are educated that this could lead to organ failure if untreated… They don’t connect that this is a deadly disease being on
dialysis is like having metastatic breast cancer, they don’t understand this and I think they need to be educated and this, I think, has a big influence on what
treatment choices the patient makes and how motivated the patient is to implement those and implement lifestyle changes.’
Preconceived ideas about treatments
‘I’ve had a number of patients say “I am not going to take steroids. You know, my uncle went crazy on steroids and I’m just not gonna take those” or “I had problems
with them in the past for some other problem” and so they have some… predisposition towards or against.’
‘There are those that are overly concerned about prednisone because they have read about all the complications, and there are those that would rather be on
prednisone than say they are taking cyclophosphamide; because they think that’s chemotherapy when they read about it on the website. So that becomes a problem.’
Literacy/health literacy of patient/parent
‘Even if I try to use literacy appropriate low technical words, I find that parents who have less education, less training or younger patients, less life experience—
parents who are younger—I find those patients have the most difficulty dealing with the instructions, the diagnosis, the complications, and the prognosis.’
‘Even when they have a higher level of understanding or education they still tend to read just enough to get to a conclusion that they want and you have to sort of give
them a broader picture and open their eyes to what all the different options are so they don’t just rely on a single report from the internet.’
Facilitators
Developing and sustaining relationships/trust between patients/families and providers
‘There’s also the continuity of the care, and there’s that sort of trust that has to be built between the patient and the physician. Those are all very dependent on how
things are going, so it’s a lot easier when, in fact, you’re very successful, and everything goes away, and their symptoms almost go away. It’s not so easy when things
aren’t going well or they’ve already been through a number of other treatments, and it hasn’t worked’
‘The nephrologist is scary… . I find that it takes a while in here for the person even able to accept this. We’re going to be friends, and we are going to need to see each
other. It’s far more than just, “I’m not certain of your diagnosis because you have proteinuria.” That takes a while’
‘Initially, there’s not a rapport. Initially, they don’t know who I am and initially, I need to make sure they… they understand that I don’t keep the information from
them. I don’t lie to them, and I will always tell them the truth. If I tell them, “You’re not to worry,” then they’re not to worry. I will tell them when to worry because I
will tell them I’m worried. I try to say that initially for the first two or three visits because we don’t know one another, but it’s still sometimes very hard.’
Inter-professional team
‘It’s a team. As I said, I see myself as being heavily reliant upon the compassion and the intelligence of my nurses to screen things, address what’s important, and to
provide that kind of day-to-day support.’
‘I always get involved… pharmacies, the dietician, the nurses. I find it and the patients find it very helpful to hear an independent second opinion. Again, it’s a
resource, and you are actually, depending on who they are, but it’s in a community setting. Sometimes, these resources are available, and it’s quite useful.’
‘I think the nursing approach is usually a much more practical lifestyle approach. We go in. Here’s the medicine. Here’s what a biopsy is. Here’s the risk of a biopsy,
and that could take a good hour just doing that, but if you leave it there you haven’t—the patients need to and want to hear that, but boy, is that 15% of what they
really need to know. They need to knowwhat am I going to do at home. It’s not likewe couldn’t do that, but in general, our nursing, social work, dietary that’s kind of
what they do and they’re much better. That’s the more complete education to get’
Providing patient/parent education
‘We have a very directive program where the nurses actually have a specific program that they go through. They teach the families, they bring them in on a separate
day; not a regular clinic day, not during your routine clinic visit. They do teaching for about two to three hours, and then they essentially begin to almost testing the
families to make sure they can do it on their own. They have them read a lot of material; they have them go through all of that process.’
Continued
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to comprehend, which meant they had unique learning needs
in comparison with patients with other illness conditions. A
number of providers stressed the importance of providing in-
formation that was ‘targeted to the patient’. This included con-
sideration of the patient’s/parent’s level of understanding about
their condition, and their ability to comprehend medical facts.
In addition to considering language preferences and health lit-
eracy, providers suggested that information should also be tai-
lored to address characteristics of the ‘condition’ as well as
patient age, developmental stage and preferred learning styles.
Providers’ perceptions of factors affecting the
decision-making process
Providers described barriers to the decision-making process
in terms of both challenges and constraints they experienced
themselves as well as those they thought were experienced by
the patient/parent (Table 3). In many instances, these chal-
lenges were interrelated (i.e. a barrier providers experienced,
such as time, might interfere with their ability to provide infor-
mation, and thus, impact the patient/parent understanding
of the disease). An overarching theme in providers’ comments
was the importance of patients’ and parents’ understanding
of NS and its treatment to support the decision-making pro-
cess. Factors that might interfere with understanding were,
therefore, considered barriers or challenges to the decision-
making process.
From the providers’ perspective, time constraints and the
complexity of explaining NS were the most significant chal-
lenges to supporting patients/parents in developing an under-
standing of NS. This complexity, coupled with a perceived lack
of robust evidence upon which to base treatment recommenda-
tions, made it difficult to provide the necessary information to
support decision-making. To some extent, this was due to the
amount of information providers felt patients and parents
needed to understand the condition, as well as the multiple
treatment and self-management decisions they had to make.
Providers also identified a number of factors they felt facilitated
or supported the decision-making process. These included the
health care team and system resources and supports, as well as pa-
tient and family characteristics. The importance of developing
and sustaining relationships as well as establishing trust between
the patient and provider was consistently identified as essential to
engaging patients and parents in the decision-making process.
Having the support of an interdisciplinary team was highlighted
by a number of providers as being essential, increasing the oppor-
tunity, expertise and time to provide patient education.
Results of the PGQ
Facilitators and barriers to guideline implementation.
Although 100% of participants were aware of the existence of
the KDIGO guidelines and 90% had read them, only 55% uti-
lized these guidelines to inform their practice. Facilitators and
barriers to guideline implementation in general are summar-
ized in Table 4. The most commonly cited facilitators included
guideline availability (91%), evidence of improved outcomes
secondary to use of guidelines (76%) and agreement with
guideline recommendations (70%). Conversely, the most com-
monly noted barriers included lack of evidence that the guide-
lines improved patient outcomes (55%), concerns about the
interpretation of evidence (55%) and lack of agreement with
guideline recommendations (45%).
Additionally, we compared provider responses based on prac-
tice setting [academicmedical center (n = 20) versus community
practice (n = 13)]. Providers in academic medical centers were
less likely to identify ‘guideline awareness’ as a facilitator (35%
versus 85%, P = 0.005), and they were more likely to give ‘lack
of agreement with recommendations’ as a barrier (60% versus
23%, P = 0.04). Overall though, there was high agreement
between perceived facilitators and barriers by setting. When
comparing providers who practiced in the USA with those who
practiced in Canada, we found few differences. American
Table 3. Continued
Facilitators
Social support
‘One of the things that I’ve noticed that seems to help is when they come with family. A lot of times, that family actually has different perspectives than the patient.
The patient’s already overwhelmed by having that diagnosis and having to undergo very potentially toxic treatments. Having the family member around, especially
if they don’t speak English as a first language, is very useful, and they also have extra questions that sometimes actually help make the decision a lot easier for the
patients.’
Table 4. Facilitators and barriers to guideline implementation
n (%)
Facilitators
Guideline availability 30 (91%)
Evidence of improved patient outcomes 25 (76%)
Agreement with recommendations 23 (70%)
Guideline awareness 18 (55%)
Congruence of guidelines with patient characteristics 18 (55%)
Organizational support for guideline implementation 18 (55%)
Resources for facilitation 18 (55%)
Perception of improved patient outcomes 16 (46%)
Congruence of guidelines with practice 12 (36%)
Time 10 (30%)
Barriers
Lack of evidence of improved patient outcomes 18 (55%)
Concern about interpretation of evidence 18 (55%)
Lack of agreement with recommendations 15 (45%)
Lack of congruence of guidelines with patient characteristics 13 (39%)
‘Too cookbook’ 13 (39%)
Guideline availability 12 (36%)
Guideline awareness 9 (27%)
Lack of time 9 (27%)
Lack of resources for facilitation 8 (24%)
Lack of congruence of guidelines with practice 7 (21%)
Lack of confidence in guideline developers 4 (12%)
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providers were more likely to give ‘guideline availability’ and
‘congruence of guidelines with practice’ as a facilitator (96% ver-
sus 71%, P = 0.04 and 46% versus 0%, P = 0.02, respectively).
They were alsomore likely to give ‘guideline availability’ as a bar-
rier (46% versus 0%, P = 0.02).
Condition-specific evaluation of the KDIGO guidelines.
The general acceptability of the guidelines varied by condition,
but overall practice was at least somewhat consistent with the
existing guidelines most of the time (Table 5). Rarely was prac-
tice completely consistent with the published guidelines. Not all
providers cared for each subset of patients. Regardless, the low-
est rates of guideline acceptability occurred in SSNS (58%),
largely due to the toxicity of proposed therapies. Other cited
reasons for deviation from the published guidelines included
different established prescribing practices, lack of availability
of recommended therapeutic agents, and concerns about effi-
cacy as well as patient characteristics and preferences. In par-
ticular, the lack of guidance in different ethnicities, women of
childbearing age, and the elderly were noted as deficiencies
within the existing KDIGO guidelines.
DISCUSSION
Our findings suggest that physicians treating the multifaceted
diseases that cause NS struggle to impart an understanding of
the chronic, relapsing and remitting nature of the condition as
well as the balance of efficacy and toxicity of a chosen therapy,
while trying to incorporate a variety of patient-specific consid-
erations and learning needs. This is a particularly challenging
task to accomplish within the existing clinic visit model and al-
ternative strategies to enhance patient understanding of their
disease and facilitate self-management are needed.
Providers currently lack adequate resources to support the
time-consuming process of explaining the complexities of NS
and intricacies of the disease course, which impacts the pa-
tients’/families’ willingness and ability to follow treatment recom-
mendations. Providers in our study recognized the variability in
patient and parent learning needs and acknowledged the potential
emotional impact that receiving a diagnosis of NS could have on a
patient or caregiver’s ability to grasp information and participate
in treatment decisions. Patient preferencesmust be a consideration
when making treatment recommendations, but our providers
highlighted the difficulty of communicating the risk/benefit ratio
of various treatment options. Having the opportunity to develop
trusting relationships and the availability of a multidisciplinary
team were identified as supports for the decision-making process,
underscoring the importance of providing ongoing opportunities
for patients and families to interact with the health care team.
However, the precise role for different members of the interdiscip-
linary team in the care of these patients remains to be determined
and studied for efficacy.
Other factors such as age, literacy levels and preferred learn-
ing styles were also identified as important considerations for
tailoring of information, and have implications for practitioners
in terms of content, timing and delivery of information. Ex-
changing information is an important component of patient-
centered communication that can be facilitated by strategies
such as asking patients about their learning needs and prefer-
ences, eliciting their understanding about their condition and
its meaning, and communicating information in a meaningful
way that helps patients evaluate and apply the information [6].
Alternative learning platforms and resources that allow patients
to learn at their own pace outside the confines of the clinic visit
require development and assessment.
The wide scope of information necessary to share with pa-
tients to facilitate shared decision-making in a limited clinical
visit time is a common challenge in chronic diseases. Much
like patients with NS, patients with other chronic conditions
such as diabetes, asthma and inflammatory bowel disease pre-
sent to their provider with varying degrees of knowledge as well
as exposure to the disease and the health care system [10–13]. In
these other conditions, shared decision-making tools and
methods have been effectively used to focus the information ex-
change to a manageable number of prioritized concepts at each
encounter, increase the quality of clinical care, and improve pa-
tient outcomes. When used effectively and consistently, pa-
tients participating in models of care that include shared
decision-making demonstrate increased knowledge, more ac-
curate risk perceptions, reduced level of internal decision con-
flict, decisions made more consistent with their values and
Table 5. Condition-specific evaluation of the KDIGO guidelines by providers treating subtypes of NSa
SSNS (n = 19) SRNS (n = 16) MCD (n = 23) FSGS (n = 24) MN (n = 27)
Do guidelines reflect current management of specific condition
Not at all consistent 0 (0%) 0 (0%) 0 (0%) 2 (8%) 0 (0%)
Somewhat consistent 14 (74%) 14 (88%) 13 (57%) 16 (67%) 17 (63%)
Completely consistent 5 (26%) 2 (13%) 10 (43%) 6 (25%) 10 (37%)
Guidelines are acceptable 11 (58%) 12 (70%) 17 (77%) 17 (71%) 20 (77%)
If not acceptable, why? (Individual counts)
Difference in prescribing practices from recommendations 3 4 2 3 1
Availability of recommended therapeutic agents 4 1 0 0 2
Concerns about efficacy of recommended therapy 4 3 2 4 4
Concerns about side effects of recommended therapy 5 4 5 5 5
Patient characteristics (comorbidity, older adults, ethnicity, etc.) 2 3 3 3 3
Patient/family preference 3 0 1 1 1
n is the number of providers who cared for the disease subtype where SSNS is steroid-sensitive nephrotic syndrome.
SRNS, steroid resistant nephrotic syndrome; MCD, minimal change disease; FSGS, focal segmental glomerulosclerosis; MN, membranous nephropathy.
aNot all providers cared for all disease subtypes.
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higher levels of trust of their providers [14]. In addition, the use
of shared decision-making has been estimated to substantially re-
duce the cost of health care [15]. The challenges identified by ne-
phrologists in this study may be mitigated by the development
and implementation of proven shared decision-making tools
and methods similar to other chronic health conditions.
With respect to the KDIGO guidelines, evidence review and
evidence-based guidelines are an important first step to optimiz-
ing patient care and practice. Although the intention of the
KDGIO guidelines was to assist with the standardization of ther-
apy in this complex patient population, gaps exist in their use in
clinical settings with the quality of evidence or the lack thereof
noted as the most significant facilitator and barrier to guideline
implementation, respectively. The guidelines rate the quality of
the evidence (A-High, B-Moderate, C-Low or D-Very Low) as
well as the strength of the recommendation (Level 1, which cor-
responds to strong in grade, or Level 2, which corresponds toweak
in grade or discretionary). The guidelines for NS are notably de-
void of Level 1A evidence [4], and providers, especially those
practicing in academic centers, identified concerns about treat-
ment efficacy. The toxicity of existing treatment options was
also noted as a significant barrier. Further, patient age, stage of
life (e.g. fertility and pregnancy), and other comorbidities, like
obesity and diabetes, may remove multiple standard agents
from the NS treatment armamentarium. The need for individua-
lized therapy impacts therapeutic decision-making of North
American nephrologists andmay limit the perceived value of clin-
ical practice guidelines with respect to facilitating PCC. One re-
cent study of Canadian nephrologists revealed considerable
variability in the uptake of the KDIGO guidelines and found
that between 15% and 46% of participants described approaches
to treatment of glomerular disease that were not congruent with
the guidelines [16]. Further, the authors reported that the lack of
availability of clinical resources, including access to specialized
clinics and expertise, standardized protocols for immunosuppres-
sion and multidisciplinary support from other health care provi-
ders, served as barriers to guideline implementation.
Our study has several important limitations. We recruited a
convenience sample of providers who were interested and willing
to participate in focus groups and interviews. Although adequate
for the qualitative portion of the study, the sample size for the
quantitative survey limited the ability to fully examine and under-
stand differences between groups (e.g. Canada versus the USA).
Furthermore, the majority of providers were from academic cen-
ters where the management of glomerular disease is of particular
interest. As such, the patients treated at these centersmay represent
a particularly complex group of patients with NS, while the views
of the providers may not reflect all perspectives and may not be
generalizable to the larger population of practicing nephrologists.
Further studies are encouraged to explore country and practice-
specific facilitators and barriers to care of patients with NS.
CONCLUSIONS
Understanding the factors clinicians take into account when
making treatment recommendations is important to help sup-
port treatment decision-making for both providers and
patients. Individualized, tailored approaches to care supported
by evidence-based practice guidelines and acknowledgement of
patient needs and preferences are warranted. The overall
concern about lack of robust evidence to support current stand-
ard therapy, and the significant side effect profile of available
agents support efforts to develop and test new, effective and
safe treatment options. The complexity of these diseases also
speaks to the need for involvement of multidisciplinary staff
as well as the adoption of effective shared decision-making
tools and learning platforms as possible approaches for sup-
porting the integration of best available evidence and patient/
family preferences while allowing exchange of information at
a pace that is unconstrained by outpatient clinic visit.
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